Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

BACKGROUND: Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient outcomes during vedolizumab treatment in UC. METHODS: Prospectively scored maintenance clinical (26.5 weeks; interquar...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Inflamm Bowel Dis
Autori principali: Battat, Robert, Dulai, Parambir S, Vande Casteele, Niels, Evans, Elisabeth, Hester, Kelly D, Webster, Edvelyn, Jain, Anjali, Proudfoot, James A, Mairalles, Ara, Neill, Jennifer, Singh, Siddharth, Chang, John T, Rivera-Nieves, Jesus, Sandborn, William J, Boland, Brigid S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Future Directions
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6327228/
https://ncbi.nlm.nih.gov/pubmed/30295781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy307
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi